Press Releases

September 14, 2026

ANGELIS Oncology today announced its launch and the advancement of ANG038, a novel long-acting investigational therapy for CNS tumors, including recurrent glioblastoma.  The company is focused on developing ANG038 to address significant unmet needs in patients with these challenging cancers.